Successful, we will reply to you quickly.OK
Please select the quantity.OK
Your message is being sent, please wait.Close
Send mail failed, please send again!Close
Products are for research use only. Not for human use. We do not sell to patients.
Vercirnon Chemical Structure
|Product name: Vercirnon|
|Cat. No.: HY-15724|
Vercirnon is a highly potent antagonist of CCR9, which has been implicated in the aetiology of inflammatory bowel diseases such as Crohn's disease.
IC50 value: <7 nM (Molt-4 cells, CCR9 transfected cell, primary derived human T cells, and murine and rat thymocytes)
in vitro: CCX282-B inhibits CCR9 mediated chemotaxis to CCL25 (IC50 <7 nM), measured in the Molt-4 cells, CCR9 transfected cell lines, primary derived human T cells, and murine and rat thymocytes. CCX282-B inhibits CCR9-mediated Ca2+mobilization and chemotaxis on Molt-4 cells with IC50 values of 5.4 and 3.4 nM, respectively.. CCX282-B inhibits chemotaxis of primary CCR9-expressing cells to CCL25 with an IC50 of 6.8 nM. CCX282-B is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC50 values of 2.8 and 2.6 nM, respectively. 
in vivo: CCX282-B also inhibits mouse and rat CCR9-mediated chemotaxis. Inhibition of CCR9 with CCX282-B results in normalization of Crohn's disease such as histopathology associated with the TNFΔARE mice. 
|M.Wt||444.93||Storage||Please store the product under the recommended conditions in the Certificate of Analysis.|
|Solvent & Solubility||
10 mM in DMSO
|1 mg||5 mg||10 mg|
|1 mM||2.2475 mL||11.2377 mL||22.4754 mL|
|5 mM||0.4495 mL||2.2475 mL||4.4951 mL|
|10 mM||0.2248 mL||1.1238 mL||2.2475 mL|
. Walters MJ, et al. Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J Pharmacol Exp Ther. 2010 Oct;335(1):61-6.
. Haberer LJ, et al. Effects of vercirnon on the activity of CYP3A4, CYP2C19 and CYP2C8 enzymes and BCRP and OATP1B1 transporters using probe substrates. Eur J Clin Pharmacol. 2014 Jan;70(1):37-45.
Cenicriviroc is an oral, dual CCR2/CCR5 antagonist, and displays potent anti-inflammatory and aninfective activity.
INCB3344 is a novel, potent and selective small molecule antagonist of the mouse CCR2 receptor; inhibits the binding of CCL2 to mouse monocytes with nanomolar potency (IC50 = 10 nM).
Maraviroc (UK-427857; Selzentry; Celsentri) is a selective CCR5 antagonist (IC50= 6.4 nM); displays potent anti-HIV-1 activity.
NSC5844 (RE640) is a bisquinoline compound with C-C chemokine receptor type 1 (CCR1)-agonistic properties.
RS 504393 is a selective CCR2 chemokine receptor antagonist (IC50 values are 98 nM and > 100 (mu)M for inhibition of human recombinant CCR2b and CCR1 receptors respectively).
TAK-220 is an orally bioavailable small-molecule CCR5 antagonist.
Other Countries & RegionsSee Worldwide Distributors